Treatment of visceral leishmaniasis: A review of current treatment practices

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 8, 2002, Pages 1101-1108

  Marty, Pierre ^a   Rosenthal, Eric ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Amphotericin B; Developing countries; Drug resistance; HIV; Liposomal amphotericin B; Miltrefosine; Pentavalent antimonials; Treatment; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIMONY DERIVATIVE; DIAMIDINE DERIVATIVE; FLUCONAZOLE; GAMMA INTERFERON; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METRONIDAZOLE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; SITAMAQUINE; STIBOGLUCONATE SODIUM; TERBINAFINE; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ACUTE PANCREATITIS; ANTIPROTOZOAL ACTIVITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; HEADACHE; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; MYALGIA; NAUSEA; NEPHROTOXICITY; PROTOZOAL INFECTION; REVIEW; TERATOGENICITY; TROPICAL DISEASE; VISCERAL LEISHMANIASIS; VOMITING; ANIMAL; DEVELOPING COUNTRY; EXPERT WITNESS; IMMUNOLOGY; MOUSE; WORLD HEALTH ORGANIZATION;

AMPHOTERICIN B; ANIMAL; ANTIPROTOZOAL AGENTS; DEVELOPING COUNTRIES; EXPERT TESTIMONY; HIV INFECTIONS; HUMAN; LEISHMANIASIS, VISCERAL; MICE; PHOSPHORYLCHOLINE; WORLD HEALTH ORGANIZATION; ANIMALS; HUMANS;

EID: 0035989260     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.8.1101     Document Type: Review

References (79)

1. The increase in risk factors of leishmaniasis worldwide
2. The epidemic of visceral leishmaniasis of Upper Nile, Southern Sudan: Course and impact from 1984 to 1994
3. Visceral leishmaniasis and HIV-1 co-infection in Southern France
4. Leishmania/HIV interaction: Immunopathogenic mechanisms
5. HIV and Leishmania coinfection: A review of 91 cases with focus on atypical locations of Leishmania
6. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy
7. A policy for leishmaniasis with respect to the prevention and control of drug resistance
8. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies
9. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies
10. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of Indian epidemic
11. Sodium antimony gluconate, amphotericin, and myocardial damage
12. Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection
13. Randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan
14. Ethiopian visceral leishmaniasis: Generic and propriarity sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome
15. Comparison of generic and propiarity sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya
16. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate
17. Novel methods for the encapsulation of meglumine antimoniate into liposomes
18. Amphotericin versus pentamidine in antimony-unresponsive kala-azar
19. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: A study of 938 cases
20. Short course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis
21. Liposomal amphotericin B in drug-resistant visceral leishmaniasis
22. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (ambisome)
23. Treatment of kala azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days
24. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex (ABLC)
25. Clinical and experimental advances in treatment of visceral leishmaniasis
26. Short course low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony
27. Comparison of three treatment regimens with liposomal amphotericin B (ambisome) for visceral leishmaniasis in India: A randomized dose-finding study
28. Chemotherapy of leishmaniasis and trypanosomiasis: Advances and failures
29. Leishmaniasis
30. Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (Ambisome)
31. Successful treatment of antimony resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus
32. Visceral leishmaniases in renal transplant recipients: Successful treatment with liposomal amphotericin B (Ambisome)
33. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B randomized trial
34. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis
35. Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone
36. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis
37. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study
38. Allopurinol in the treatment of visceral leishmaniasis
39. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol
40. Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar
41. Treatment of visceral leishmaniasis with meglumine and allopurinol
42. Combination therapy in Kala-azar
43. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases)
44. Randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis
45. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani
46. Hexadecylphosphocholine: Oral treatment of visceral leishmaniasis in mice
47. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in Balb/c mice
48. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei
49. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms
50. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites
51. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis
52. Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine
53. Trial of oral miltefosine for visceral leishmaniasis
54. Oral treatment of visceral leishmaniasis with miltefosine
55. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
56. Short-course of oral miltefosine for treatment of visceral leishmaniasis
57. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
58. Données récentes sur le traitement de la leishmaniose viscérale
59. Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches
60. Phase II efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis
61. Phase II trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi
62. Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma and interleukin-2-independent
63. Effect of treatment with interferon-gamma alone in visceral leishmaniasis
64. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma
65. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis
66. Treatment of mediterranean visceral leishmaniasis
67. Conclusions and recommendations of the IVth WHO joint meeting on Leishmania-HIV co-infections
68. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
69. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy
70. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy
71. Efficacy and safety of liposomal amphotericin B (Ambisome) for visceral leishmaniasis in endemic developing countries
72. Drug resistance in Indian visceral leishmaniasis
73. La leishmaniose viscérale en Algérie. Recensement des cas de leishmaniose viscérale
74. Human visceral leishmaniasis in Alpes-Maritimes, France: Epidemiological characteristics for the period 1985-1992
75. Leishmania and human immunodeficiency virus coinfection: The first ten years
76. Visceral leishmaniosis in HIV-positive patients: Primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts
77. Epidemiological, clinical and therapeutic features of kala-azar (including post kala-azar dermal leishmaniasis)